THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company“), a primary helium company, is pleased to announce its financial and operating results for the nine months ended June 30, 2026 (the “Period”). Selected financial and operational information is outlined below and should...

Havila Kystruten (HKY) delivered a solid operational performance in the second quarter of 2026 and a significant increase in earnings. The Group reported a positive EBITDA of MNOK 98, compared to MNOK 79 in Q2 2025, representing a 24% improvement year-over-year. The EBITDA margin improved to 21%, up from 19% in the same period last year. The Group also reported a positive net profit of MNOK 3 for the first half of 2026, the first positive half-year result in the company history, driven in part by currency gains. Revenue growth and operational performanceTotal operating revenues reached MNOK 479 in Q2 2026, an increase of 15% year-over-year. Ticket revenue grew by 10% to MNOK 287, driven by high occupancy levels. Onboard revenue grew by 32% to MNOK 85. Onboard revenue per passenger night increased by 6% to NOK 790. Contractual revenues...

SECOND-QUARTER RESULTS The Group’s order coverage and order portfolio were strengthened in the second quarter, while its financial results were affected by the previously announced write-down on the Nordhavn Tunnel.  Revenue decreased 6% to DKK 2.5 billion. MT Højgaard Danmark’s revenue was largely unchanged, as several major projects are making only modest contributions during their start-up phase this year. Enemærke & Petersen’s revenue decreased 14% due to lower activity in the parent company, while Raunstrup reported stable operations.EBIT was a loss of DKK 77 million following a DKK 175 million write-down on the Nordhavn Tunnel joint venture. Excluding joint ventures, the operating profit (EBIT) was DKK 97 million (2025: DKK 115 million). MT Højgaard Danmark’s operating profit (EBIT), excluding joint ventures, was DKK 106...

3 year cost saving and synergy projects yielded record Q2 EBITDA Highlights of the Group Group results excl. discontinued operations                                                                                                                                                                     Q2 2026Total Revenue of € 127.7 million ((5.9)% compared to € 135.7 million in Q2 2025) Operating Profit € 0.1 million ((83.3)% compared to € 0.6 million in Q2 2025) EBITDA € 11.3 million (+2.7% compared to € 11.0 million in Q2 2025) Adjusted EBITDA € 14.0 million ((10.8)% compared to € 15.7 million in Q2 2025)H1 2026Total Revenue € 245.1 million ((2.5)% compared to €251.3  million in H1 2025)Operating Profit € (1.9) million (+65.5% compared to € (5.5)million in H1 2025)EBITDA € 18.0 million (+15.4% compared to € 15.6 million...

MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) — CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026). The Company has declared a dividend of $0.05 per ordinary share. “CLINUVEL’s cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,” said Mr Peter Vaughan, CLINUVEL’s Group Chief Financial Officer. “This position provides us with flexibility to pursue an expansion strategy, continue investing through market cycles in key strategic areas, and allocate capital based on opportunity rather than necessity. As CLINUVEL builds its operations and presence in the capital markets in the...

KALDVIK AS (KLDVK) reports operating income in Q2 amounted to EURm 11.3 (EURm 7.9), while operating loss before fair value adjustment of biomass and production tax was EURm -3.3 (EURm -4.3). Harvest amounted to 1,840 (1,235) tonnes in Q2 2026. The Company maintains harvest guidance for 2026 at approximately 17,000 tonnes. The Q2 2026 presentation and Half-Year 2026 report are attached. Kaldvik AS publishes full financial statements semi-annually (half-year and annual reports). WebcastA webcast presentation of the Q2 2026 results will be held at 10:00 CEST / 08:00 UTC today, 27 August 2026. The presentation will be held in English by CEO Vidar Aspehaug and CFO Þórunn Ragnarsdóttir. A Q&A session will follow. The webcast can be accessed at www.kaldvik.is/live Contacts:Vidar Aspehaug, CEO+47 913 05 017 (mobile) Þórunn Ragnarsdóttir,...

Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. – IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued progress towards its profitability improvement trajectory. The period was marked by strong commercial momentum, notably in Proton Therapy and RadioPharma Solutions, as well as the strengthening of IBA’s leadership team and Board to support the Group’s growth and execution of its strategic roadmap.Sustained growing revenue and enhanced profitability in H1, marked by positive net resultNet sales rose 6% vs. H1 2025, to €323.7 million, thanks to well-executed backlog conversion across segments Gross margin increased to 33.7% vs. 29.5% in H1 2025, driven by equipment profitability mix and improved execution in Proton...

ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2026. HIGHLIGHTS Financial highlights:Profit for the period of USD 364.4 million in Q2 2026. EBITDA for the same period was USD 552.8 million. CMB.TECH’s contract backlog stable at USD 3.26 billion with the addition of 2 x 2-year CSOV time charters and 1 x 1-year VLCC time charter​ Intention to distribute an amount of USD 0.64 per share. Fleet highlights:Delivery of 9 newbuilding vessels (Q2 + Q3 to date):Newcastlemaxes: Mineral Latvija, Mineral Magyar, Mineral Eesti, Mineral Lietuva VLCCs: Morini Suezmaxes: Cap Grace, Cap Joseph CSOV: Windcat Haarlem CTV: FRS Windcat 65 CMB.TECH and Fortescue...

VANCOUVER, British Columbia, Aug. 27, 2026 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG”), a vertically integrated data center and digital assets technology company, today announces its fiscal third quarter 2026 unaudited financial results. All financial references are in Canadian Dollars unless specified otherwise. Readers are encouraged to review the Company’s June 30, 2026 quarterly unaudited financial statements and management’s discussion and analysis thereof for an assessment of the Company’s performance and applicable risk factors, available at www.sedarplus.ca. Q3 2026 Financial Results HighlightsRevenue: $6.4 million, down 13% from $7.3 million in Q2 2026 and down 45% from $11.6 million in Q3 2025 Bitcoin Received from Mining: 61.9 bitcoin, down 10% from 68.8...

SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTSAs of June 30, 2026, the company’s total revenue was approximately RMB1,696 million for the first half of 2026 (2026H1), a 45% increase compared to 2025, which was made possible by the rise in sales revenue of pharmaceutical products. In particular, the domestic sales revenue of our core product, toripalimab, reached approximately RMB1,299 million, around 36% more than in 2025. In addition, out-licensing revenue also increased by approximately RMB152 million, an approximately...